FDA needs 3 more months to review cancer drug vandetanib

01/9/2011 | Google

The FDA pushed back an approval decision on vandetanib, a drug for medullary thyroid cancer, after maker AstraZeneca submitted a plan for risk evaluation and mitigation. The agency is scheduled to complete its review by April 7.

View Full Article in:

Google

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR